GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ambee Pharmaceuticals Plc (DHA:AMBEEPHA) » Definitions » Net-Net Working Capital

Ambee Pharmaceuticals (DHA:AMBEEPHA) Net-Net Working Capital : BDT0.00 (As of . 20)


View and export this data going back to 2004. Start your Free Trial

What is Ambee Pharmaceuticals Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Ambee Pharmaceuticals's Net-Net Working Capital for the quarter that ended in . 20 was BDT0.00.

The industry rank for Ambee Pharmaceuticals's Net-Net Working Capital or its related term are showing as below:

DHA:AMBEEPHA's Price-to-Net-Net-Working-Capital is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.735
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Ambee Pharmaceuticals Net-Net Working Capital Historical Data

The historical data trend for Ambee Pharmaceuticals's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ambee Pharmaceuticals Net-Net Working Capital Chart

Ambee Pharmaceuticals Annual Data
Trend
Net-Net Working Capital

Ambee Pharmaceuticals Semi-Annual Data
Net-Net Working Capital

Competitive Comparison of Ambee Pharmaceuticals's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, Ambee Pharmaceuticals's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ambee Pharmaceuticals's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ambee Pharmaceuticals's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Ambee Pharmaceuticals's Price-to-Net-Net-Working-Capital falls into.


;
;

Ambee Pharmaceuticals Net-Net Working Capital Calculation

Ambee Pharmaceuticals's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in . 20 is calculated as

Ambee Pharmaceuticals's Net-Net Working Capital (NNWC) per share for the quarter that ended in . 20 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Ambee Pharmaceuticals  (DHA:AMBEEPHA) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Ambee Pharmaceuticals Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Ambee Pharmaceuticals's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Ambee Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
184/1 Tejgaon Industrial Area, Dhaka, BGD, 1208
Ambee Pharmaceuticals Plc formerly Ambee Pharmaceuticals Ltd manufactures a wide range of pharmaceutical products in Bangladesh. It is engaged in the business of manufacturing drugs and medicine and sales. Its products are sold in the form of tablets, capsules, liquids, gels, and injectables.

Ambee Pharmaceuticals Headlines

No Headlines